Researchers published an implantable platform that periodically 'charges' engineered immune cells in vivo, restoring function and extending anti‑tumor activity. Preclinical data show the device reactivated CAR‑iNKT cells and other adoptive cell therapies inside tumor beds, overcoming local exhaustion and microenvironment suppression. Independent coverage described the implant as both a biologic and device innovation: it supplies localized stimulatory cues or cytokines to rejuvenate transferred cells, reducing the need for repeated dosing and offering a path to longer durable responses with lower systemic toxicity.